20 APR 2017 Alteogen to enter late-stage study of Herceptin biosimilar
THE INVESTOR] Alteogen is accelerating the development of a biosimilar version of the world’s top breast cancer drug Herceptin to join two other Korean firms in challenging big pharma Roche.
29 MAR 2017 Korean firm to transfer biosimilar tech to Chinese partner
Alteogen, a Korean developer of biosimilars, said Wednesday it would transfer the technology of its ALT-L2, a biosimilar product of breast and gastric cancer treatment Herceptin, to China’s Qilu Pharm
29 DEC 2016 Alteogen patents
Date Alteogen patents (updated weekly) - BOOKMARK this page
22 DEC 2016 Alteogen clears phase 1 trial of Herceptin biosimilar in Canada
DISCLOSURE] Alteogen (196170) said on Dec. 22 that its biosimilar of Roche’s breast cancer antibody Herceptin has cleared phase 1 clinical trials in Canada.
7 Oct 2016 Alteogen receives patent in Japan
Oct 7 Alteogen Inc :